Pediatric Psychopharmacology Update Institute 2019

Pediatric Psychopharmacology Update Institute is organized by American Academy of Child and Adolescent Psychiatry (AACAP) and will be held from Jan 25 - 26, 2019 at New York Marriott at the Brooklyn Bridge, Brooklyn, New York, United States of America. This CME Conference has been approved for a maximum of 11.25 AMA PRA Category 1 Credits.

AACAP’s 2019 Pediatric Psychopharmacology Update Institute:
Early Treatment Intervention: When, What, and For How Long? links the latest findings on the treatment of ADHD, substance abuse, depressive disorders, irritability, suicidal/self-injurious behaviors, psychosis and schizophrenia, anxiety, and high-risk mood and psychotic disorders.

Eight top child and adolescent psychiatric researchers detail their approaches to treatment of psychiatric disorders from preschool through transitional age youth with the latest psychiatric medications, discussing medication selection, effectiveness, and expected adverse events. They review the latest data that address balancing benefits and risks across this age range using first-line psychotropic medications in the treatment of youth. In addition to the known, FDA-approved treatments, the speakers describe other relevant treatments that work in conjunction with psychotropic medication.

At the end of the Institute, clinicians will have thoroughly reviewed current publications on psychopharmacologic treatments across the age range, so they can discuss how efficacy, safety, and outcome data is translated into clinical practice.

Educational Learning Objectives :
At the conclusion of this CME activity, the participant will be able to:
•  Discuss the latest evidence-based psychopharmacology data that specify indication and adverse events for medical treatment for important psychiatric disorders from preschool through young adulthood with stimulant medications, second-generation antipsychotic medications, lithium, and selective serotonin reuptake inhibitors.
•  List the first- and second-line psychopharmacological medication choices and dose ranges for youth who present with ADHD, substance abuse, depressive disorders, psychosis, irritability, suicidal behavior, and prodromal or are at high risk for mood and psychotic disorders.
•  Present information on starting and stopping medications, how long a medication needs to be tried before switching to another medication, and the methods of phasing in a new medication while withdrawing the other, especially in regards to patients at different ages.
•  List the barriers that militate against the successful treatment with psychiatric medications for children, adolescents, and young adults with psychiatric disorders, as well as possible solutions including those that may not require the use of medication.

Additional details will be posted as soon as they are available.